BMS-247550 in Treating Patients With Stage IV Melanoma

Completed · Phase 2

Conditions studied: Recurrent Melanoma, Stage IV Melanoma

In brief

Phase II trial to study the effectiveness of BMS-247550 in treating patients who have stage IV melanoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Key facts

Study ID: NCT00036764
Run by: National Cancer Institute (NCI)
People needed: 88
Starts: 2002-02-01
Last updated by the study team: 2013-01-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histologically or cytologically confirmed stage IV melanoma
At least 1 measurable lesion
Greater than 20 mm by conventional techniques
Greater than 10 mm by spiral CT scan
Known brain metastases allowed if all of the following criteria are met:
Radiologically stable for at least 6 weeks after completion of whole brain radiotherapy
Stable at time of study
No mass effect present radiologically
No concurrent steroids to control symptoms of brain metastases
Performance status - ECOG 0-2
Performance status - Karnofsky 60-100%
At least 3 months
Absolute neutrophil count at least 1,500/mm\^3
Platelet count at least 100,000/mm\^3
Bilirubin normal
AST/ALT no greater than 2.5 times upper limit of normal (ULN)
Creatinine no greater than 1.5 times ULN
No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmia
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No prior severe allergic reactions (grade III or IV or grade II not responsive to steroids) to taxanes or medications containing Cremophor EL
No pre-existing grade 2 or greater peripheral neuropathy

Where it is running

New York University Clinical Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.